3B Blackbio Dx Limited (3BBLACKBIO)
Investor Presentation
Investor Presentation - H1 2026-27
- Consolidated revenue 81.77 Cr (+45.6% y-y); PAT 27.00 Cr (-2.5% y-y)
- MDx division revenue 77.08 Cr (+52.8% y-y); PAT 27.07 Cr (-1.4% y-y)
- MDx growth outlook: 15-20% revenue growth for FY27 despite geopolitical tensions
- Coris acquisition consolidated fully; EBITDA loss reduced by 45%
- Expanding global presence in 70+ countries; new product launches in molecular diagnostics
- Focus on strategic M&A in USA and capacity utilization at ~65%
- IVDR certification progressing; new automated extraction system TRUElute® launched
- Long-term contracts under reagent-rental model contribute 20-25% revenue
- Active participation in global events to boost international market penetration
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 3BBLACKBIO — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add 3BBLACKBIO to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on 3B Blackbio Dx Limited
Important.
The summary above is generated automatically from 3B Blackbio Dx Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.